AbbVie Gets New FDA Accelerated Approval for Epkinly
By Sabela Ojea
AbbVie said that the U.S. Food and Drug Administration approved Epkinly as the first and only T-cell bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.
The pharmaceutical company on Wednesday said that the Epkinly treatment has shown deep and durable responses for many patients.
Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, but AbbVie will be responsible for further global commercialization.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
June 26, 2024 19:50 ET (23:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations